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Abstract 
 
Buprenorphine is the opioid most commonly used in laboratory mice. To maintain 
therapeutic serum levels, repeated injections are required. Oral self-administration is 
an alternative but has been criticized to be unreliable. Here we analyse voluntary 
intake and water/injection combinations for their reliability to achieve effective drug 
supply. Mice were assigned to one of five groups: a) naïve (N); b) buprenorphine via 
water for 24 h (W); c) buprenorphine via two injections during light, and via water 
during dark phase (IW2); d) buprenorphine via three subcutaneous injections during 
light phase and water for 24 h (IW3) or e) surgery plus buprenorphine via three 
subcutaneous injections during light phase and water for 24 h (S). Drinking 
frequency, water and food intake, activity, body mass progression, blood serum 
concentrations and behavioral pain indicators were determined. Water intake was not 
decreased due to buprenorphine or surgery. Administration of buprenorphine resulted 
in an increase of activity in IW3 animals and a decrease in body mass. Food 
intake decreased in IW2, IW3 and S mice. All treatment groups showed mean serum 
concentrations higher than the targeted value throughout dark phase. 
Sporadic drinking events and variable individual serum concentrations during light 
phase suggest the use of a combination protocol, to ensure therapeutic serum levels 
and minimization of pain indicators after surgery (S). 
 
Keywords: analgesia, buprenorphine, oral administration, pain 
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Zusammenfassung 
 
Buprenorphin ist eines der am häufigsten angewendeten Schmerzmittel in der Maus. 
Um langfristig therapeutisch wirksam zu sein, muss es repetitiv injiziert werden. Eine 
Alternative ist die Aufnahme über das Trinkwasser. Um diese Darreichungsform zu 
testen, wurden die Tiere in fünf Gruppen eingeteilt: a) naive Tiere (N); b) 
Buprenorphin im Trinkwasser für 24 h (W); c) zwei Buprenorphin Injektionen während 
der Hellphase, im Trinkwasser während der Dunkelphase (IW2); d) drei Buprenorphin 
Injektionen während der Hellphase, im Trinkwasser für 24 h (IW3) oder e) Operation 
und drei Injektionen während der Hellphase und im Trinkwasser für 24 h (S). 
Trinkfrequenz, Wasser- und Futteraufnahme, Aktivität, Gewichtsverlauf, 
Serumkonzentrationen und Schmerzindikatoren wurden erfasst. Die 
Wasseraufnahme wurde durch Gabe von Buprenorphin bzw. durch die Operation 
nicht reduziert. Buprenorphin führte zu vermehrter Aktivität und Gewichtsabnahme in 
der IW3 Gruppe. Buprenorphin führte zu reduzierter Futteraufnahme in der IW2, IW3 
und S Gruppe. In den mit Buprenorphin behandelten Gruppen wurden während der 
Dunkelphase mittlere Serumkonzentrationen über dem angestrebten Wert erreicht. 
Wegen der sporadischen Wasseraufnahme in der Hellphase empfiehlt es sich, 
Injektionen in der Hellphase mit einer Buprenorphin Gabe im Trinkwasser in der 
Dunkelphase zu kombinieren, um eine kontinuierliche therapeutische Versorgung 
sicherzustellen. 
 
Stichworte: Analgesie, Buprenorphin, orale Administration, Schmerz 
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1. Introduction 
 
Ethical, legal and scientific considerations require the effective prevention and 
treatment of pain in laboratory animals (Institute of Laboratory Animal Resources 
(U.S.) Committee on Pain and Distress in Laboratory Animals 1992). 
Today, buprenorphine is one of the most widely used opioid analgesics in the 
treatment of pain in laboratory and companion animals (Roughan and  Flecknell 
2002). It is fast acting and potent, with mixed agonist-antagonist activity at classical 
opioid receptors and has been shown to be effective in a variety of pain models 
(Christoph, Kogel et al. 2005). However, to maintain therapeutically effective serum 
levels in mice, injections may be required more than four times in 24 h (Jirkof, 
Tourvieille et al. 2015). 
Repeated post-surgical injections of analgesic drugs require restraint and 
manipulation of the animal. Handling and restraint alone may impose stress even on 
healthy animals (Meijer, Spruijt et al. 2006, Cinelli, Rettich et al. 2007), and are 
assumed to evoke additional pain, or to increase existing pain in animals with fresh 
surgical wounds (Jirkof, Tourvieille et al. 2015). Both the lack of efficient post-surgical 
pain treatment and additional handling/restraint might induce a stress response, 
which will have effects on physiological and endocrine function and therefore might 
impair the recovery of the animals. This stress response may be a significant 
confounder of experimental data, leading to imprecise results and therefore to 
increased inter- and intra-animal variation (Moberg 1999). 
Attempts have been made to overcome these problems and to assure  continuous 
and stress-free administration of buprenorphine analgesia. Several authors have 
described depot formulations of analgesia for rodents (Foley, Liang et al. 2011, 
Carbone, Lindstrom et al. 2012, Healy, Tonkin et al. 2014, Jirkof, Tourvieille et al. 
2015). For example, Jirkof et al. (Jirkof, Tourvieille et al. 2015) presented a sustained 
release formulation of buprenorphine that offers a long-lasting, assured blood 
concentration, resulting in an anti-nociceptive effect, and suggested relief of post- 
surgical pain for 24–48 h, without causing additional stress to the animals. However, 
while sustained-release formulations of buprenorphine have become commercially 
available  on  the  US  market  (Animalgesics  ®  for  Mice,  Animalgesic  Labs     Inc, 
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Millersville, MD, USA; Buprenorphine HCl CIII SR, Wildlife Pharmaceuticals Inc, 
Windsor, CO, USA), they are not available in Europe to date. 
Oral self-administration of buprenorphine is another promising approach to 
administering analgesia without the negative effects of handling. Nevertheless, oral 
self-administration has been criticized as less effective than subcutaneous treatment 
in rats (Martin, Thompson et al. 2001, Thompson, Kristal et al. 2004, Thompson, 
DiPirro et al. 2006) and compromised bioavailability due to first-pass metabolism, 
referring to reduced drug concentration due to the drug being metabolized before it 
reaches systemic circulation, is a known obstacle in this administration route 
(Brewster, Humphrey et al. 1981). Despite these concerns, several studies in mice 
and rats have shown that buprenorphine has sufficient analgesic efficacy when 
administered orally. Several routes of oral administration have been described, such 
as mixing buprenorphine with flavored gelatin (Liles, Flecknell et al. 1998), Nutella ® 
(Goldkuhl, Jacobsen et al. 2010, Kalliokoski, Jacobsen et al. 2011), gel delivery 
systems (Hovard, Teilmann et al. 2015) or with the regular diet of the mice (Molina- 
Cimadevila, Segura et al. 2014). 
While these routes of administration have been shown to provide analgesia, they 
also have their limitations. For instance, food neophobia is a well-known obstacle in 
the oral administration of analgesics in mice. Habituation to new food items is 
necessary in order to ensure sufficient intake and resulting therapeutic drug levels 
(Liles, Flecknell et al. 1998, Goldkuhl, Jacobsen et al. 2010, Kalliokoski, Jacobsen et 
al. 2011, Hovard, Teilmann et al. 2015). Moreover, even after habituation, the latency 
to ingestion of the drug, as well as the total amount ingested by the animals, might be 
difficult to anticipate (Hovard, Teilmann et al. 2015). Providing buprenorphine mixed 
with the regular diet might overcome the problem of food neophobia, as stated by 
Molina-Cimadevila et al. (Molina-Cimadevila, Segura et al. 2014). Nonetheless, 
medicated food items need to be prepared prior to administration, which might be 
costly and time consuming depending on the chosen food medium (Liles, Flecknell et 
al. 1998, Goldkuhl, Jacobsen et al. 2010, Kalliokoski, Jacobsen et al. 2011, Hovard, 
Teilmann et al. 2015). Alternatively, providing analgesia mixed with drinking water  is 
a promising route of administration (Hayes, Raucci et al. 2000, Jessen,  Christensen 
et al. 2007) since tap water is readily available at every facility and mixtures can be 
prepared within minutes. 
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The present study aimed to explore whether administering buprenorphine in drinking 
water offers a reliable treatment option for pain management in mice or if a 
combination with buprenorphine injections may be necessary for reliable drug supply. 
In a first experiment three analgesic protocols were tested: administration via drinking 
water (W), a combination of two buprenorphine injections during the light phase and 
administration via drinking water in the dark phase (IW2) and a combination of three 
buprenorphine injections during the light phase and administration via drinking water 
for 24 h (IW3). Drinking behaviour, spontaneous water and food intake, blood serum 
concentrations reached by the drug over time, and behavioural modifications possibly 
evoked by the drug were assessed. 
We hypothesize that laboratory mice drink the buprenorphine treated water regularly 
and in sufficient amounts, at least during the dark phase, to reach continuous 
therapeutic buprenorphine serum concentrations and also to minimize pain indicators 
after one-side sham embryo transfer. We therefore tested in a second experiment the 
most promising analgesic protocol (IW3) for its reliability in assuring pain relief in 
surgically treated mice, using clinical investigation and behaviour-based pain 
assessment. 
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2. Materials and Methods 
 
2.1 Ethics statement 
 
The animal housing and experimental protocols were approved by the Cantonal 
Veterinary Office, Zurich, Switzerland, under license no. 181/2012, and were in 
accordance with Swiss Animal Protection Law and conform to European Directive 
2010/63/EU of the European Parliament and of the Council on the Protection of 
Animals used for Scientific Purposes and to the Guide for the Care and Use of 
Laboratory Animals (Worlein, Baker et al. 2011). 
 
2.2 Animals and standard housing conditions 
 
The animals were 110 female C57BL/6J mice obtained at the age of 4–5 weeks 
(Charles River, Sulzfeld, Germany). Their health status was monitored by a health 
surveillance programme according to FELASA guidelines. The mice were free of all 
viral, bacterial, and parasitic pathogens listed in FELASA recommendations, except 
for Helicobacter species (Mahler, Berard et al. 2015). 
 
 
Mice were housed in groups of four to eight animals for three weeks prior to testing. 
All animals were maintained in Eurotyp III clear transparant plastic cages 
(Techniplast, Hohenpeissenberg, Germany) with a 12-hour light/dark cycle (lights on 
at 8:00) with artificial light (approximately 40 lx in the cages), controlled temperature 
and relative humidity of 21  1C° and 55  10%. They were fed a pelleted and 
extruded mouse diet (Kliba No. 3436, Provimi Kliba, Kaiseraugst, Switzerland) ad 
libitum and had unrestricted access to drinking water. Autoclaved dust-free sawdust 
bedding (80–90 g per cage; LTE E-001 Abedd, Indulab), autoclaved hay (8–12 g per 
cage; Winzeler, Affoltern am Albis, Switzerland) and one nestlet™ (5 cm x 5cm), 
consisting of cotton fibres (Indulab AG, Gams, Switzerland), as nesting material and 
cardboard shelters (Ketchum Manufacturing, Brockville, Canada) were provided. 
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2.3 Treatment protocols 
 
Naïve mice (N): Naïve mice received tap water for the experimental period. 
Buprenorphine administration via drinking water (W): Temgesic (Temgesic solution, 
0.3mg/ml, Reckitt Benckiser, Switzerland), a water-soluble buprenorphine medicinal 
product, was administered in the drinking water of the mice. Temgesic was diluted 
using tap water to a dose of 0.009 mg/ml drinking water. At the beginning of the light 
phase (8:00), mice were provided with a freshly prepared bottle of buprenorphine- 
treated water. The dose of buprenorphine was chosen to be approximately 10 times 
higher than the subcutaneous dose (Liles, Flecknell et al. 1998, Roughan and 
Flecknell 2002), assuming that a mouse would drink approximately 3 ml of the 
buprenoprhine-treated water per day. 
Buprenorphine administration via two injections during light phase and drinking water 
during dark phase (IW2): Mice were injected subcutaneously twice at a commonly 
used dose of 0.1 mg buprenorphine /kg body mass, at 4 h (12:00) and 10 h (18:00) 
after the beginning of the light phase. Shortly before the injection, Temgesic was 
diluted in sterile NaCL (0.9%) so that the injection volume was 2 µl/g body mass. 
Following the second injection, the animals were provided with buprenorphine-treated 
drinking water overnight, prepared as described above. Injection times were chosen 
dependent on the assumption that, if surgery is performed at the onset of the light 
phase, post-operative pain management should start 4 h later (as pre-operative 
administered buprenorphine loses its efficacy after 4–6 h). The second injection time 
was chosen to be 6 h after the first injection and, at the same time, mice were 
provided with buprenorphine-treated water. We assumed that mice would start to 
drink the buprenorphine-treated water regularly from the onset of the dark phase, 2 h 
after presentation. 
Buprenorphine administration via three injections during light phase and drinking 
water for 24 h (IW3): 
Mice were injected subcutaneously three times at a commonly used dose of 0.1 mg 
buprenorphine/kg body mass, with the beginning of the light phase (8:00) and at 4 h 
(12:00) and 8 h (16:00) after the beginning of the light phase. Injection times were 
chosen dependent on the assumption that, if surgery is performed at the onset of the 
light phase pre-emptive pain management should be administred before surgery. 
Post-operative pain management should start 4 h after first injection. The third 
injection time was chosen to be 4 h after the second injection. Additonally, mice were 
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provided with buprenorphine-treated drinking water, prepared as described above, 
from the beginning of the light phase (8:00) for 24 h. 
 
 
 
Experimental design, experimental animal housing conditions and data acquisition: 
Forty mice were assigned randomly to one of five groups in equal numbers (n=8) for 
behavioural assessment (drinking behaviour analyses, activity, food and water intake, 
body mass progression, with additional pain scoring in the surgery group): a) naïve 
mice (N), b) buprenorphine administration via drinking water (W), c) buprenorphine 
administration via two injections during light phase and drinking water during dark 
phase (IW2), d) buprenorphine administration via three injections during light phase 
and drinking water for 24h (IW3) or e) surgery plus buprenorphine administration via 
three injections during light phase and drinking water for 24h (S). 
After behavioural assessment mice were allowed to recover for 2-3 weeks  in 
standard housing conditions. Except for the surgery group, all other mice (n=32) were 
used additionally for blood serum sampling after the recovery period, to reduce the 
total number of animals used in this study. 
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2.4 Experiment 1 
 
 
2.4.1 Behavioural assessment 
Mice were housed individually in a special observation cage with raised plastic (465 
mm high) walls instead of a cage grid. The observation cage had the same floor 
space as the standard cage and was equipped with a water bottle fixed outside of the 
cage with the nipple extended into the cage. Their usual diet and a nestlet were 
provided on the cage floor of the observation cage. Prior to experiments, mice were 
allowed to become accustomed to the new housing conditions for three days. 
 
2.4.2 Drinking behavior 
Behaviour was recorded digitally in the absence of a human observer with infrared 
sensitive cameras (Ikegami). Each cage was filmed with a single camera; cameras 
and infrared light sources were attached 1.5 meters above the cages. The recorded 
material (24 hours of continuous footage) was analyzed visually; time points of water 
consumption and drinking frequencies were recorded. 
 
2.4.3 Activity analyses 
Videos recorded as described above on the first day of treatment were analyzed with 
automated tracking software (EthovisionXT 7, Wageningen, The Netherlands). The 
distance (in cm) moved by the animal was assessed automatically (movement of 
animal`s center point was tracked) to measure static behaviours, i.e. resting, 
grooming etc., as well as horizontal locomotion. 
 
2.4.4 Body mass, food and water intake 
Body mass progressions, as well as food and water consumption were measured at 
the beginning of the light phase one day before experiment and on day one and two. 
Weights were obtained by using a precision balance (PR 2003, Delta Range, Mettler- 
Toledo AG, Greifensee, Switzerland) up to an accuracy of two decimal places. 
 
2.4.5 Buprenorphine serum concentration 
Mice were group-housed in standard cages as described above. Cages were 
assigned randomly to one of three experimental groups as follows: 
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Administration via drinking water (W): Six animals were bled at one of six time points 
(day 1: 12:00, 16:00, 18:00, 22:00; day 2: 2:00, 6:00). 
Administration via two injections during light phase and drinking water during dark 
phase (IW2): Six animals were bled at one of five time points (day 1: 16:00, 18:00, 
22:00; day 2:  2:00, 6:00). 
Administration via three injections during light phase and drinking water for 24 h 
(IW3): Six animals were bled at one of six time points (Day 1: 12:00, 16:00, 20:00, 
22:00, Day 2:  2:00, 6:00). 
Time points were chosen depending on the buprenorphine administration protocol 
applied. Previous studies showed that subcutaneous injections of buprenorphine 
resulted in serum concentrations thought to be therapeutic for at least 4 h (4). Since 
W and IW3 animals were provided with buprenorphine at 8:00, the first measurement 
time for those groups was set at 12:00, 4 h after first presentation, respectively after 
first injection. 
In IW2 animals, the first time point set was 16:00, 4 h after first buprenorphine 
injection. For all protocols, subsequent measurements were performed at intervals no 
longer than 4 h. 
Blood was sampled by sublingual vein puncture under sevoflurane anesthesia. The 
amount collected was < 20% of the total blood volume of the animal (Diehl, Hull et al. 
2001, Heimann, Kasermann et al. 2009, Heimann, Roth et al. 2010). 
Blood was centrifuged and the serum stored at –20°C until further analysis. 
Buprenorphine serum concentrations were determined by Ultraperformance liquid 
chromatography tandem mass-spectrometry by a commercial laboratory, accredited 
for medical laboratory diagnostics according to DIN EN ISO 15189:2007 (MVZ Labor 
Dessau GmbH, Germany). 
 
2.5 Experiment 2 
 
 
2.5.1 Behavioural assessment 
Drinking behaviour, home cage activity, food and water intake, as well as body mass 
progression, were monitored analogous to experiment 1. 
After evaluation of data from experiment one, we assumed that pain relief could be 
assured using IW3 as the analgesic protocol for the surgery group. 
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2.5.2 Surgical procedure 
The experiment began with a subcutaneous injection of buprenorphine with the 
beginning of the light phase (8:00). Forty-five minutes after injection, animals were 
transferred in transport cages (i.e. standard cages with filter top) to a  nearby 
operating theatre. Mice were anaesthetized with sevoflurane (Sevorane,  Abbott, 
Baar, Switzerland) as mono-anaesthesia. The anaesthetic gas was provided with a 
rodent inhalation anaesthesia apparatus (Provet, Lyssach, Switzerland); oxygen was 
used as carrier gas. After induction of anaesthesia in a perspex induction chamber 
(7–8% sevoflurane, 600 mL/min gas flow), animals were transferred to a warmed (39 
± 1◦C) operating table, and anaesthesia was maintained via nose mask.  Eye 
ointment was applied, the fur was clipped and the operating field disinfected with 
ethanol (70%). Mice underwent a one-side sham embryo transfer. The incision in the 
abdominal muscle wall was closed with absorbable sutures (Vicryl, 6/0 polyglactin 
910, Ethicon Ltd, Norderstedt, Germany), and the skin was closed using skin staples 
(Precise, 3M Health Care, StPaul, MN, USA). Surgery was completed within 3–4 min, 
anaesthesia lasted 6–8 min. While regaining consciousness animals stayed for ~10 
min on the warmed table before being transferred back to the animal room. Animals 
were allowed to recover fully from anaesthesia in the transport cage for one hour in a 
warming cabinet (32°C) prior to subsequent behavioural observation. 
 
2.5.3 Pain scoring 
Animals were transferred to an observation chamber at 1, 3, 5, 7 and 24 hours after 
the animals had undergone surgery. After ten minutes of habituation clinical 
investigation and behaviour-based pain assessment lasted three minutes per animal 
and was performed by a trained and blinded observer. According to a routinely used 
scoring system documenting the general condition of an animal (Arras, Rettich et al. 
2007), abnormalities of body condition (e.g. sunken flanks), fur condition (e.g. ruffled 
coat), eyes (e.g. discharge), breathing (e.g. irregular) and posture  (e.g. hunched 
back) were registered, and the wound was checked. Additionally, changes in facial 
expression, namely orbital tightening and the ear position (Langford, Bailey et al. 
2010) were judged. Symptoms were converted into scores according to a scoring 
system (Table 1). 
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2.6 Statistical analyses 
 
 
Power calculation for group size determination was performed with G*Power 3.1. 
Statistical analyses were performed with SPSS 22 software (IBM, Armonk, NY, USA). 
All data were tested for normal distribution and homogeneity of variance (Shapiro- 
Wilks, Levene’s test). 
Mean and standard deviation of the mean were calculated for all parameters. One 
way analyses of variance (ANOVA) were performed for percentage change in body 
mass (% change compared with baseline measurements one day before 
experiments), ∆ weight of food pellets and water bottles (∆ compared with 
measurements one day before the experiment), as well as for center point distance 
moved during 24 h of activity analyses, followed by post hoc tests (Bonferroni) to 
show significant differences between groups. 
Significance for all statistical tests was established at p≤ 0.05. 
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3. Results 
 
3.1 Experiment 1 
 
 
3.1.1 Behavioural assessment 
3.1.1.1 Drinking behaviour 
While water intake during the dark phase was frequent and regular, intake during the 
light phase was rather sporadic and infrequent in all groups. The overall circadian 
pattern of drinking events appears unchanged in response to buprenorphine 
treatment (Figure 1A). 
 
3.1.1.2 Activity analyses 
Naïve animals moved a mean distance of 1284±365 cm within 24 h. Distance moved 
was higher in mice receiving buprenorphine treatment in all groups  compared to 
naïve mice (F (5, 39)=3.616, p=0.009); however, these differences were only 
significant in IW3 animals (p=0.005, Figure 2 A). 
 
3.1.1.3 Body mass, food and water intake 
Body mass: Mice weighed on average 21±1.7 g at 24 h before the start of the 
experiment. No significant difference in percent body mass progression between 
groups was found (F (5, 42)=1.633, p=0.172, Figure 2 B). 
Food intake: Naïve mice ate in general 3.6±0.4 g of food pellets a day. Significant 
differences between groups were found (F (5, 40)=8.763, p≤0.0001). Compared with 
naïve mice, food intake was decreased significantly in IW2 and IW3  animals, 
whereas animals which had only been provided with buprenorphine in the drinking 
water did not decrease their food intake significantly (W) (IW2: p=0.001, IW3: 
p=0.023, Figure 2 C). 
Water intake: Naïve mice drank in general 4.8±0.3 g of water a day. Water intake did 
not differ significantly between the treatment groups (F (5, 42) =1.851, p=0.124, 
Figure 2D). 
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3.1.2 Buprenorphine serum concentration 
Mean serum concentrations of buprenorphine remained high throughout the dark 
phase in all buprenorphine-treated groups (Table 2). In W and IW3 animals, mean 
serum concentrations remained high throughout the entire investigation period, while 
IW2 animals showed constant high serum concentrations only during the dark phase. 
Individual comparison of serum concentrations revealed that in W (Figure 3) and IW2 
(Figure 4) several individual mice showed serum concentrations beneath the 
therapeutic level at times, whereas all IW3 (Figure 5) mice tested showed constant 
high serum concentrations throughout the entire investigation period. 
 
3.2 Experiment 2 
 
 
3.2.1 Behavioural assessment 
3.2.1.1 Drinking behaviour 
The pattern of drinking behaviour was not altered in response to surgery. While 
drinking events during the dark phase occurred frequent and regular, drinking during 
the light phase appeared rather sporadic and unreliable, comparable to observations 
acquired in experiment 1 (Figure 1B). 
 
3.2.1.2 Activity analyses 
Naïve animals moved a mean distance of 1284±365 cm within 24 h. Compared to 
naïve animals, distance moved was insignificantly higher after surgery (F (5, 
39)=3.616, p=0.772, Figure 2 A). 
 
3.2.1.3 Body mass, food and water intake 
Body mass: Mice weighed on average 23±1.1 g before surgery. No significant 
difference between treatment groups was found (F (5, 42)=1.633, p=0.438, Figure 2 
B). 
Food intake: Naïve mice ate in general 3.6±0.4 g of food pellets a day. Significant 
differences between groups were found (F (5, 40)=8.763, p≤0.0001). Compared with 
naïve mice, food intake was decreased significantly after surgery (p≤0.0001, Figure 2 
C). 
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Water intake: Naïve mice drank in general 4.8±0.3 g of water a day. Mice did not 
decrease their water intake significantly after surgery (F (5, 42) = 1.851, p=1.000, 
Figure 2D). 
 
3.2.2 Pain scoring 
Clinical investigation revealed no physical complications from the surgical procedure 
performed or of the analgesic treatment, e.g. skin irritation at the injection site, and 
only minor impairment of animals resulting in clinical investigation scores of 0.13±0.4 
at 3 h after surgery was noticed. Narrowing of the orbital area or pulled back ears 
were rare events seen at 1, 3 and 5 h after surgery (0.81±0.8, 0.69±0.9, 0.13±0.4). 
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4. Discussion 
 
The aim of this study was to explore whether administering buprenorphine with 
drinking water offers a reliable treatment option for pain management in mice or 
whether a combination with buprenorphine injections may be necessary for reliable 
drug supply. In a first experiment, three protocols were tested in pain free mice: 
administration via drinking water (W), a combination of two buprenorphine injections 
during the light phase plus administration via drinking water in the dark phase (IW2) 
and a combination of three injections during light phase as well as administration via 
the drinking water for 24 h (IW3). All protocols resulted in mean drug serum 
concentrations assumed to be therapeutically effective at most of the sampling time 
points. Nevertheless, blood serum concentrations of individual mice revealed that 
only the IW3 protocol - continuous supply of buprenorphine with the drinking water 
and injections every four hours during the light phase – proved to ensure continuous 
therapeutic blood serum concentrations of buprenorphine in all of the tested pain free 
mice. Therefore, in a second experiment, IW3 was tested in a standard surgery 
model and proved to provide prolonged, clinically relevant and reliable analgesia. 
 
Administration of buprenorphine for pain relief by voluntary, oral intake requires a 
vehicle that is ingested immediately after first presentation and regularly over time. A 
study in rats by Jessen et al. (Jessen, Christensen et al. 2007) showed that mixing 
buprenorphine with drinking water induced a significant increase in paw withdrawal 
latency in the hot-plate-test. However, this latter study also showed that rats  tended 
to decrease their daily water intake when provided with buprenorphine-treated water. 
Therefore, the first aim of the present study was to assess the willingness of 
laboratory mice to ingest buprenorphine treated water. The frequency of drinking 
events as well as the total amount ingested in 24 h was measured. Mice started to 
drink the buprenorphine treated water immediately and regularly after first 
presentation, so that no habituation period was needed, and total water intake was 
not reduced due to buprenorphine administration. This observation of immediate drug 
intake was remarkable as several authors have reported the need for habituation 
periods when providing mice with medicated food items (Liles, Flecknell et al. 1998, 
Kalliokoski,  Jacobsen  et  al.  2011,  Hovard,  Teilmann  et  al.  2015).  Water  intake 
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appeared frequent and relatively reliable during the dark phase but rather sporadic 
and less frequent during the light phase due to circadian activity in mice. Drinking 
pattern was not obviously altered by buprenorphine administration (drinking water 
and/or injection) or by surgical intervention as seen in the descriptive display of 
drinking events in figure 1, hinting that voluntary, oral intake may be a possible 
stress-free administration route for mice. 
Nevertheless, due to its first-pass metabolism (Brewster, Humphrey et al. 1981), the 
efficacy of orally administrated buprenorphine has raised concerns. On the other 
hand, several studies have shown that buprenorphine has sufficient analgesic 
efficacy in rodents when administered orally in high concentrations (Liles, Flecknell et 
al. 1998, Goldkuhl, Jacobsen et al. 2010, Molina-Cimadevila, Segura et al. 2014, 
Hovard, Teilmann et al. 2015). Moreover, Jessen et al. (Jessen, Christensen et al. 
2007) showed that, in rats, buprenorphine administered in drinking water induced 
antinociception of a greater magnitude and longer duration of action than repeated 
injections. This possible advantage of the oral over the injection route is also 
supported by a study performed by Kalliokoski et al. (Kalliokoski, Jacobsen et al. 
2011), in which buprenorphine administered with Nutella® led to higher serum 
concentrations compared to those in mice provided with buprenorphine 
subcutaneously. In humans, the blood serum concentration of buprenorphine leading 
to effective analgesia is targeted to be approximately 0.5 ng/mL or higher (Evans and 
Easthope 2003), whereas in rodents blood serum concentrations of 1 ng/mL are 
assumed to be effective (Yassen, Olofsen et al. 2005). In our study we observed 
higher mean and in many cases higher individual blood serum concentrations after 
oral administration of buprenorphine (1 mg/kg) than after subcutaneous injections 
(0.1 mg/kg). This could be due to the higher dosage in the drinking water, or it could 
be that oral administration might have resulted in better absorption and greater 
bioavailability than the subcutaneous route, as already suggested by Jessen et al. 
(Jessen, Christensen et al. 2007). Mean blood serum concentrations remained higher 
than the targeted therapeutic value throughout the whole observation period in W 
and IW3 animals. In IW2 animals, mean blood serum concentrations remained 
therapeutic until 4 h after the first injection, but dropped at 6 h after the first injection 
(18:00) to values below those thought to be therapeutic, while during the drinking 
water administration in the dark phase, IW2 animals showed high mean serum 
concentrations until the next day. This shows that buprenorphine provides    clinically 
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relevant serum concentrations, and therefore potential pain relief, only for 4–6 hours 
after injection, as already suggested by Jirkof et al. (Jirkof, Tourvieille et al. 2015). 
Therefore, an application interval of 8 h, as commonly practiced, appears too long 
and might lead to periods with insufficient analgesia in animals undergoing lasting 
pain—a concern also expressed by others (Gades, Danneman et al. 2000, Carbone, 
Lindstrom et al. 2012, Jirkof, Tourvieille et al. 2015). 
A serious concern in administering drugs with drinking water is the possible reduction 
of water intake due to surgery and the reliability of providing every individual animal 
with sufficient analgesia in group housed mice. Jirkof et al. (Jirkof, Cesarovic et al. 
2012) showed that mice undergoing a mild to moderate impact surgery like a one- 
side sham embryo transfer, even when not provided with analgesia, did not decrease 
their water intake post-surgery. Those animals that had been provided  with 
analgesia, on the other hand, increased their water intake post-surgery,  at least 
during the first six hours after surgery (day phase). In our study mice did neither 
decrease their water intake post-surgery nor did they considerably change their 
drinking behaviour, suggesting that mice drank the buprenorphine treated water in 
sufficient amounts to provide clinically relevant analgesia. 
However, most importantly, inter-individual differences in drinking behaviour -namely 
frequency and intervals of drinking events- led to high variability in serum 
concentrations of individual mice in four out of five protocols, resulting in periods 
beneath the targeted serum concentration and therefore potential lack of pain relief. 
In consideration of these results, surgery was only performed in combination with 
protocol IW3, a combination of continuous supply of buprenorphine treated water and 
three injections of buprenorphine during light phase, which proved to result in 
continuous, high serum concentrations of buprenorphine. Pain scoring of animals 
that underwent surgery with the IW3 protocol resulted in low pain scores. In a 
comparable study, using the same line, sex, housing conditions, surgery techniques 
and pain indicators animals with saline treatment after surgery reached modified 
grimace scales of 3.1+/-0.9 and clinical scores of 1.3+/-0.7 one hour after surgery 
while animals treated with buprenorphine sustained release formulation had scores of 
0.7+/-0.4 and 1.1+/-0.9 respectively (Jirkof, Tourvieille et al. 2015). Based on the 
comparison to these previously observed scores, we assume that the low pain 
scores, of 0.81±0.8 and 0.13±0.4, assessed one hour after surgery in our study (S), 
hint on effective pain relief in animals receiving IW3 treatment. 
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However, in light of our results, caution should be exercised when administering 
analgesics solely via drinking water in experiments that evoke more than mild pain. In 
such cases, combined protocols (continuous supply via drinking water plus repeated 
injections) might be necessary. If stress induced by repeated restraint and injection is 
of concern sustained release formulations may offer an elegant solution to overcome 
repeated subcutaneous injections and still provide long-lasting and sufficient pain 
relief in mice (Foley, Liang et al. 2011, Carbone, Lindstrom et al. 2012, Healy, Tonkin 
et al. 2014, Jirkof, Tourvieille et al. 2015). In any case, mice need to be monitored 
closely after painful interventions so that if pain is observed, rescue analgesia, e.g. 
subcutaneous injections, can be applied. 
Regardless of the route of administration, since buprenorphine may have several 
side effects (increased locomotor activity, and a decrease in food intake and body 
mass gain), a careful balancing of the impacts of possible side-effects against 
expected benefits should be performed (Bomzon 2006, Adamson, Kendall et al. 
2010, Healy, Tonkin et al. 2014). Jirkof et al. (Jirkof, Tourvieille et al. 2015) showed 
that home cage activity after injection of a sustained release formulation (2.2 mg/kg 
body mass) increased significantly and persisted for more than 24 h, resulting in 
disruption of circadian rhythm, possibly due to the high buprenorphine concentration. 
In the experiment presented here, all buprenorphine treated animals also showed a 
tendency of higher home cage activity compared to N animals, with a significant 
increase in IW3, probably due to continuous high buprenorphine serum 
concentrations in this group. In the surgery group on the other hand, which had also 
been supplied with buprenorphine in the drinking water and three injections during 
light phase this increase in activity was no longer significant, probably due to longer 
resting periods after surgery. Food intake was reduced significantly compared to N 
animals, in response to buprenorphine administration (IW2, IW3 and S). We did not 
observe other side effects, such as abnormal behaviours or sedation, as observed 
when mice receive high doses of buprenorphine (personal communication M. 
Guarnieri). 
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5. Conclusion 
 
In conclusion, administering buprenorphine solely via drinking water may be a pain 
treatment option in, at least female C57BL/6J, mice. However, sporadic water intake 
during the light phase and high individual variability in achieved serum concentrations 
suggests the combination of drinking water plus buprenorphine injections every 4 h in 
the light phase in order to guarantee continuous therapeutic serum concentrations. In 
our study the combination of two injections during light phase and drinking water 
administration during dark phase still appeared insufficient for 24 hour therapeutic 
serum concentrations, whereas three injections in a four hour interval during the light 
phase in combination with drinking water administration for 24 h guaranteed 
continuous therapeutic serum concentrations in all animals. Animals that received 
this protocol showed very low pain scores after surgery indicating analgesic efficiency 
of this combination protocol. To overcome concerns of reduced water intake due to 
pain directly after surgery pre-emptive injections of buprenorphine appear to be an 
important measure. 
Nevertheless, the side effects of buprenorphine, as well as the effects of repeated 
restraint and injections regarding animal wellbeing and experimental readout must be 
considered. Such effects might be acceptable when pain relief in experiments with 
more than mild pain has to be assured and if high buprenorphine intake in individual 
animals, when combining oral and injection administration, is acceptable. Sustained 
release formulations might overcome such drawbacks in experiments involving 
severe or moderate pain in the future. 
In experiments involving mild pain only, buprenorphine administration via drinking 
water alone could be a pain treatment option; however, individual animals could 
possibly suffer from insufficient pain relief at times. 
Therefore, when choosing the appropriate analgesia protocol for mice, a careful 
balancing of the impacts of possible side-effects against the expected pain impact 
has to be a mandatory component of animal experiment design. 
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6. Figures & Tables 
 
 
 
 
 
 
 
Figure 1: Drinking behaviour over 24 h: Water intake was frequent during the dark phase 
but rather sporadic during the light phase in all groups. Each row of dots represents the 
drinking events for an individual mouse. Data are solely descriptive, no statistical analysis 
was applied. A: Water intake in naïve (N) and with buprenorphine treated (W, IW2, IW3), 
pain free mice. B: Water intake in surgically treated mice, provided with three buprenorphine 
injections during light phase and via drinking water for 24 h. (N = Naïve, W = Buprenorphine 
administration via drinking water, IW2 = Buprenorphine administration via two injections 
during light phase and drinking water during dark phase, IW3 = Buprenorphine administration 
via three injections during light phase and via drinking water for 24h, S = surgery plus 
buprenorphine administration via three subcutaneous injections and drinking water for 24 h.). 
Dark phase is indicated by a dark grey bar and light phase by a light grey bar. Drinking 
events are depicted as dots for each individual. Buprenorphine injections are indicated by 
downward  pointing  grey arrows,  provision  of buprenorphine  treated water  is  indicated by 
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horizontal grey arrows. Surgery time is indicated by a downward pointing black  arrow, 
labeled with an “S”. n=8 animals per treatment group. 
 
 
 
 
 
 
Figure 2: A Activity: Mean (±SD) distance in cm moved during 24h. Distance moved was 
higher in mice receiving buprenorphine treatment than in naïve mice (p= 0.009); however, 
these differences were only significant in IW3 animals (p=0.005). B Body mass 
progression: Mean (±SD) percentage body mass change at 24h after the start of the 
experiment. No significant differences between groups were found (p=0.172). C Food 
consumption: Mean (±SD) daily food intake in grams. Compared with naïve animals, food 
intake decreased significantly after buprenorphine administration in IW2, IW3 and  S 
treatment groups (IW2: p=0.001; IW3: p=0.023; S= p≤ 0.0001). D Water consumption: 
Mean (±SD) daily water intake in grams. Water intake did not differ significantly between 
groups (p=0.990). 
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N = Naïve, W = Buprenorphine administration via drinking water, IW2 = Buprenorphine 
administration via two injections during light phase and drinking water during dark phase, 
IW3 = Buprenorphine administration via three injections during light phase and via drinking 
water for 24h, S = surgery plus buprenorphine administration via three subcutaneous 
injections and drinking water for 24 h. n=8 animals per treatment group. * Significant (p≤ 
0.05) differences between experimental groups. 
 
 
 
 
 
 
 
 
 
 
Figure 3: Individual Serum concentrations of buprenorphine in W animals at the time points 
shown. The targeted blood concentration for effective buprenorphine treatment in rodents is 
1 ng/ml (indicated by the black solid horizontal line). Provision of buprenorphine in the drinking 
water is indicated by a horizontal arrow. Light phase is indicated by the light grey bar, dark 
phase is indicated by the dark grey bar. n=6 animals per time point. 
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Figure 4: Individual serum concentrations of buprenorphine in IW2 animals at the time points 
shown. At 6 h after the first injection (18:00) 90% of the sampled mice show buprenorphine 
serum concentrations beneath values assumed to be effective. 
The targeted blood concentration for effective buprenorphine treatment in rodents is 1 ng/ml 
(indicated by the black solid horizontal line). Buprenorphine injections are indicated by 
downward pointing arrows, provision of buprenorphine treated water is indicated by a 
horizontal arrow. Light phase is indicated by the light grey bar, dark phase is indicated by the 
dark grey bar. n=6 animals per time point. 
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Figure 5: Individual serum concentrations of buprenorphine in IW3 animals at the time points 
shown. All mice sampled show buprenorphine serum concentrations assumed therapeutically 
effective at all time points. The targeted blood concentration for effective buprenorphine 
treatment in rodents is 1 ng/ml (indicated by the black solid horizontal line). Buprenorphine 
injections are indicated by downward pointing arrows, provision of buprenorphine treated 
water is indicated by a horizontal arrow. Light phase is indicated by the light grey bar, dark 
phase is indicated by the dark grey bar. n=6 animals per time point. 
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Parameter    Scores 
Facial expression     
 orbital tightening 
 
 
 
 
 
 ear position 
 narrowing of the orbital area, a tightly 
closed eyelid, or an eye squeeze 
(orbital muscles around the eyes 
contracted) 
 
 ears pulled back or rotate outwards 
and/or back, away from the face. space 
between the ears may appear wider 
 
 
 
not present = 0, 
moderately = 1, 
severe = 2 
General condition    
 spontaneous 
behaviour 
 
 
 
 
 
 
 posture 
 coat condition 
 
 
 eyes 
 body condition 
 
 wound 
 
 
 
 
 
 movement 
 sudden movements, backwards 
movements, transient involuntary 
muscular contraction of any body part, 
kicking with hind paws, licking/biting the 
wound, highly aggressive, increased 
vocalization 
 
 
 hunched, arched back, crouched 
 
 ruffled, dirty, unkempt, piloerection, hair 
loss (alopecia) 
 
 discharge 
 sunken flanks, swollen areas, ascites 
 
 dirty, bloody, uncleaned, signs of self- 
injury, signs of inflammation or 
necrosis, i.e., unusual color (e.g., red, 
pale) or swollen 
 
 apathetic, sedated, decelerated, 
crawling, immobile, lameness, tiptoe 
gait 
 
 
 
 
 
 
 
 
 
 
 
 
not present = 0, 
present = 1 
 
 
Table 1: Scoring system for clinical investigation and behaviour based pain assessment in 
laboratory mice. In total a max score of 11 can be reached (modified from Jirkof et al. 2015) 
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Time point 
Group 
 
12:00 
 
16:00 
 
18:00 
 
20:00 
 
22:00 
 
02:00 
 
06:00 
 
W 
 
5.72±6.85 
 
10.41±4.77 
 
9.00±10.74 
 
n/a 
 
8.05±8.83 
 
5.02±4.50 
 
4.36±4.57 
 
IW2 
 
n/a 
 
1.9±1.60 
 
0.12±0.30 
 
n/a 
 
6.52±7.61 
 
6.50±6.44 
 
6.86±8.12 
 
IW3 
 
9.77±2.16 
 
7.88±3.17 
 
n/a 
 
8.11±3.73 
 
11.97±7.92 
 
10.29±5.04 
 
17.22±10.36 
 
 
Table 2: Mean (±SD) serum concentrations of buprenorphine in W, IW2 and IW3 animals at 
the time points shown. In W and IW3 animals mean serum concentrations of buprenorphine 
were higher than the targeted value (1ng/ml) throughout the whole observation period.  In 
IW2 animals mean buprenorphine serum concentrations decreased beneath the targeted 
value at one time point: 6 h after the first injection (18.00). n=6 animals per time point. 
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